I'm LongbridgeAI, I can summarize articles.Editas Medicine (EDIT.US) reported zero vaso-occlusive crises in sickle cell patients and transfusion independence in beta-thalassemia cases. Rogers Corp's advanced materials revenue rose 9%, while Youdao's learning services surged 26.8% as niche innovation gains momentum.
Editas Medicine (EDIT.US) stole the spotlight at June's European Hematology Association meeting with RUBY trial results showing zero vaso-occlusive crises in 18 sickle cell patients treated with reni-cel. The parallel EdiTHAL trial demonstrated transfusion independence in seven beta-thalassemia patients maintaining hemoglobin above 9g/dL for 12 months - validating CRISPR's potential for one-time cures. This propelled EDIT.US' quarterly revenue to USD 11.89 million, a 320% sequential jump.
Dermata Therapeutics (DRMA.US) advanced its topical gene therapy for skin cancer into late-stage trials, while Pharmacyte Biotech (PMCB.US) optimized manufacturing for its diabetes cell therapy. Rogers Corp (ROG.US) saw its advanced electronics segment grow 9.1% to USD 117.5 million as EV demand surged. Youdao Inc (DAO.US) reported 26.8% year-on-year growth in learning services to RMB 795.6 million, offsetting declines in online advertising.
Kaspi.kz (KSPI.US) expanded digital banking services across Kazakhstan, and Heidmar Maritime (HMR.US) capitalized on LNG shipping rebounds. WisdomTree's India Earnings ETF (EPI.US), Acceleration Holdings (ACCV.US), and space logistics firm Momentus (MNTS.US) each carved niches in emerging markets, reflecting sector-wide innovation beyond headline-grabbing biotech breakthroughs.